Works Cited

1. Centers for Disease Control and Prevention. Heart Disease. Atrial Fibrillation. Available at https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Last accessed October 2, 2020.

2. Wyse DG, Van Gelder IC, Ellinor PT, et al. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014;63(17):1715-1723.

3. American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2006;48(4):854-906.

4. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86(5):516-521.

5. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate versus rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165(3):258-262.

6. Flaker GC, Nasr S. Immediate management of atrial fibrillation: state of the art. Card Electro Rev. 2001;5(2-3):183-186.

7. Medical News Today. New Research in Atrial Fibrillation. Available at https://www.medicalnewstoday.com/mnt/releases/8304#1. Last accessed October 2, 2020.

8. Luderitz B, Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med. 2000;160(12):1749-1757.

9. Heart Rhythm Society. Atrial Fibrillation. Available at https://www.upbeat.org/heart-rhythm-disorders/atrial-fibrillation#axzz3CwpfdbKy. Last accessed October 2, 2020.

10. Conover MB. Understanding Electrocardiography. 8th ed. St Louis, MO: Mosby; 2002.

11. National Heart, Lung, and Blood Institute. Atrial Fibrillation. Available at https://www.nhlbi.nih.gov/health-topics/atrial-fibrillation. Last accessed October 2, 2020.

12. National Heart, Lung, and Blood Institute. How the Heart Works. Available at https://www.nhlbi.nih.gov/health-topics/how-heart-works. Last accessed October 2, 2020.

13. Vallerand AH, Sanoski CA. Davis's Drug Guide for Nurses. 14th ed. Philadelphia, PA: FA Davis Co.; 2014.

14. Hall JE. Guyton and Hall Textbook of Medical Physiology. 12th ed. Philadelphia, PA: WB Saunders Co.; 2011.

15. Parmet S, Lynm C, Glass RM. Electrocardiograms. JAMA. 2003;289(16):2166.

16. Dubin D. Rapid Interpretation of EKGs. 6th ed. Tampa, FL: Cover Publishing Co.; 2000.

17. Grauer K. A Practical Guide to ECG Interpretation. 2nd ed. St Louis, MO: Mosby; 1998.

18. Cohen M, Naccarelli, GV. Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm. J Cardiovasc Electrophysiol. 2008;19(8):885-890.

19. Woods SL, Froelicher ES, Motzer SA, Bridges EJ. Cardiac Nursing. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

20. Naccarelli GV, Dell'Orfano JT, Wolbrette DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol. 2000;85(10a):36-45.

21. Nattel S, Burstein B, Dobrev D. Basic science for the clinical electrophysiologist: atrial remodeling and atrial fibrillation: mechanisms and implications. Circulation. 2008;1:62-73.

22. Nattell S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. JACC. 2014;63(22):2335-2345.

23. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267.

24. Borke J. Emergent Management of Atrial Flutter. Available at https://emedicine.medscape.com/article/757549-overview. Last accessed October 2, 2020.

25. Olshansky B. Atrioventricular Nodal Reentry Tachycardia. Available at https://emedicine.medscape.com/article/160215-overview. Last accessed October 2, 2020.

26. LexiComp Online. Available at https://online.lexi.com/lco/action/login. Last accessed October 2, 2020.

27. Moses S. Atrial Fibrillation Rate Control. Available at https://fpnotebook.com/CV/EKG/AtrlFbrltnRtCntrl.htm. Last accessed October 2, 2020.

28. U.S. Food and Drug Administration. Lexiscan (Regadenoson) and Adenoscan (Adenosine): Drug Safety Communication—Rare but Serious Risk of Heart Attack and Death. Available at https://wayback.archive-it.org/7993/20170112164514/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm. Last accessed October 2, 2020.

29. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164(1):55-60.

30. Rosenthal L. Atrial Fibrillation. Available at https://emedicine.medscape.com/article/151066-overview. Last accessed October 2, 2020.

31. Mayo Clinic. Atrial Fibrillation. Available at https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/symptoms-causes/syc-20350624. Last accessed October 2, 2020.

32. MedlinePlus. Atrial Fibrillation or Flutter. Available at https://medlineplus.gov/ency/article/000184.htm. Last accessed October 2, 2020.

33. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151.

34. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

35. Ramirez D, Engel KG, Tang TS. Language interpreter utilization in the emergency department setting: a clinical review. J Health Care Poor Underserved. 2008;19(2):352-362.

36. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care: perspectives of Chinese and Vietnamese immigrants. J Gen Intern Med. 2003;18(1):44-52.

37. American Heart Association. Guidelines and Statements. Available at https://professional.heart.org/en/guidelines-and-statements. Last accessed October 2, 2020.

38. Frost JL, Campos-Outcalt D, Hoelting D, et al. AAFP Pharmacologic Management of Newly Detected Atrial Fibrillation: Updated Clinical Practice Guideline. Available at https://www.aafp.org/dam/AAFP/documents/patient_care/clinical_recommendations/a-fib-guideline.pdf. Last accessed October 2, 2020.

39. Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol. 2000;85(10A):12D-19D.

40. Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol. 2000;85(10A):3D-11D.

41. European Heart Rhythm Association. 2016 ESC guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(38):2893-2962.

42. American College of Cardiology, American Heart Association. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(18):1935-1944.

43. Kalus JS. Pharmacologic management of atrial fibrillation: established and emerging options. J Manag Care Pharm. 2009;15(6-B Suppl):S10-S18.

44. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence. Available at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Last accessed October 2, 2020.

45. Merck Manual Home Health Handbook. Overview of Generic Drugs and Drug Naming. Available at https://www.merckmanuals.com/home/drugs/brand-name-and-generic-drugs/overview-of-generic-drugs-and-drug-naming. Last accessed October 2, 2020.

46. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120-2127.

47. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian trial of atrial fibrillation investigators. N Engl J Med. 2000;342(13):913-920.

48. Korantzopoulos P, Siogas K. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(25):2618-2621.

49. Wood MA, Ithiel A, Fuller BA. Ibutilide and calcium channel blockers: is there an interaction? Cardiovasc Rev Rep. 2003;24(6):326-330.

50. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med. 2003;163(7):777-785.

51. Mead GE, Elder AT, Flapan AD, Cordina J. Electrical cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev. 2017;(11):CD002903.

52. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351(23):2373-2383.

53. Daily Med. Available at https://dailymed.nlm.nih.gov/dailymed/. Last accessed October 2, 2020.

54. PubMed Health. Diltiazem. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Diltiazem. Last accessed October 2, 2020.

55. PubMed Health. Verapamil. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Verapamil. Last accessed October 2, 2020.

56. PubMed Health. Metoprolol. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Metoprolol. Last accessed October 2, 2020.

57. Wooten JM, Earnest J, Reyes J. Review of common adverse effects of selected antiarrhythmic drugs. Crit Care Nurs Q. 2000;22(4):23-38.

58. Cordina J, Mead GE. Pharmacological cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev. 2017;(11):CD003713.

59. Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med. 2004;164(7):709-720.

60. Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion. Circulation. 2000;102(18):2309-2320.

61. MedlinePlus. Procainamide. Available at https://medlineplus.gov/druginfo/meds/a682398.html. Last accessed October 2, 2020.

62. Mandrola J. Digoxin Stuns in RATE-AF Trial. Available at https://www.medscape.com/viewarticle/936544#vp_1. Last accessed October 2, 2020.

63. Lindeboom JE, Kingma JH, Crijns HJ, Dunselman PH. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol. 2000;85(8):1031-1033.

64. Marinelli A, Capucci A. Antiarrhythmic drugs for atrial fibrillation. Expert Opin Pharmacother. 2011;12(8):1201-1215.

65. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation versus antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293(21):2634-2640.

66. Dave J. Torsade de Pointes. Available at https://emedicine.medscape.com/article/1950863-overview#a1. Last accessed October 2, 2020.

67. Mitchell LB. Long QT Syndrome and Torsades de Pointes Ventricular Tachycardia. Available at https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmias-and-conduction-disorders/long-qt-syndrome-and-torsades-de-pointes-ventricular-tachycardia. Last accessed October 2, 2020.

68. Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol. 2010;106(5):673-676.

69. Pfizer. Tikosyn (Dofetilide): Important Safety Information. Available at https://labeling.pfizer.com/ShowLabeling.aspx?id=639. Last accessed October 2, 2020.

70. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;(9):CD005049.

71. Jaiswal P, Attar BM, Yap JE, et al. Acute liver failure with amiodarone infusion: a case report and systematic review. J Clin Pharm Ther. 2018;43(1):129-133.

72. U.S. Food and Drug Administration. FDA Drug Safety Communication: Revised Dose Limitation for Zocor (simvastatin) When Taken with Amiodarone. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-dose-limitation-zocor-simvastatin-when-taken-amiodarone. Last accessed October 2, 2020.

73. Stoschitzky K, Stoschitzky G, Lercher P, Brussee H, Lamprecht G, Lindner W. Propafenone shows class Ic and class II antiarrhythmic effects. Europace. 2016;18(4):568-571.

74. Raijpurohit N, Aryal SR, Khan MA, Stys AT, Stys TP. Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. S D Med. 2014;67(4):137-139.

75. American College of Cardiology/American Heart Association. 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaboration with the Heart Rhythm Society. Circulation. 2006;114(15):1654-1668.

76. Beinart SC. Synchronized Electrical Cardioversion. Available at http://emedicine.medscape.com/article/1834044-overview#a01. Last accessed October 2, 2020.

77. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):429S-456S.

78. Sultan A, Steven D, Rostock T, et al. Intravenous administration of magnesium and potassium solution lowers energy levels and increases success rates electrically cardioverting atrial fibrillation. J Cardiovasc Electrophysiol. 2011:23(1):54-59.

79. Celebi OO, Celebi S, Canbay A, Erqun G, Aydogdu S, Diker E. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion. Cardiology. 2011;118(3):168-174.

80. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49(15):1642-1648.

81. Korantzopoulos P, Kalantzi K, Siogas K. Goudevenos JA. Long-term prognostic value of baseline C-reactive protein in predicting recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol. 2008;31(10):1272-1276.

82. Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69(3):425-432.

83. Zipes DP, Calkins H, Daubert JP, et al. 2015 ACC/AHA/HRS advanced training statement on clinical cardiac electrophysiology (a revision of the ACC/AHA 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion). Heart Rhythm. 2016;13(1):E3-E37.

84. Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014;63(1):40-48.

85. Gerstenfeld EP, Everett TH 4th. Internal atrial defibrillation revisited: how low can we go? J Am Coll Cardiol. 2014;63(1):49-51.

86. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.

87. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104-123.

88. U.S. Food and Drug Administration. Label and Approval History: BETAPACE AF (Sotalol HCI). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021151s009lbl.pdf. Last accessed October 2, 2020.

89. Tamargo J, Lopez-Farre A, Caballero R, Delpon E. Dronedarone. Drugs Today (Barc). 2011;47(2):109-133.

90. Rosei EA, Salvetti M. Dronedarone: an emerging therapy for atrial fibrillation. Ther Adv Cardiovasc Dis. 2010;4(3):155-164.

91. Brenner R, Delacretaz E. Dronedarone for the management of atrial fibrillation. Swiss Med Wkly. 2010;141:w13158.

92. Schweizer PA, Becker R, Katus HA, Thomas D. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther. 2011;6:27-39.

93. U.S. Food and Drug Administration. Severe Liver Injury Associated with the Use of Dronedarone (Marketed as Multaq). Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-severe-liver-injury-associated-use-dronedarone-marketed-multaq. Last accessed October 2, 2020.

94. Spiezia L, Prandoni P. Prevention of thromboembolic complications in patients with atrial fibrillation. Minerva Cardioangiol. 2008;56(6):643-652.

95. Marinigh R, Lip GY, Lane DA. Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother. 2010;11(14):2331-2350.

96. Centers for Disease Control and Prevention. Heart Disease: Atrial Fibrillation. Available at https://www.cdc.gov/heartdisease/atrial_fibrillation.htm. last accessed October 2, 2020.

97. Jauch EC. Ischemic Stroke. Available at https://emedicine.medscape.com/article/1916852-overview. Last accessed October 2, 2020.

98. Centers for Disease Control and Prevention. Preventing Stroke: What You Can Do. Available at https://www.cdc.gov/stroke/prevention.htm. Last accessed October 2, 2020.

99. Centers for Disease Control and Prevention. Stroke Risk. Available at https://www.cdc.gov/stroke/risk_factors.htm. Last accessed October 2, 2020.

100. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645.

101. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235-240.

102. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-1277.

103. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.

104. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163:936-943.

105. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056.

106. Lip GY, Nieuwlat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.

107. Atrial Fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457.

108. Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012;125(8):e13-e23.

109. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510.

110. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410-1416.

111. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747.

112. CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk. Available at https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk. Last accessed October 2, 2020.

113. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648-661.

114. Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012;125(8):e13-e23.

115. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860-865

116. Ajam T, CHADS2 Score for risk assessment in atrial fibrillation. Available at https://emedicine.medscape.com/article/2172597-overview. Last accessed October 2, 2020.

117. Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557-563.

118. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001;37(2):475-484.

119. ESPRIT Study Group, Halkes PH, van Gijn J, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol. 2007;6(2):115-124.

120. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-974.

121. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.

122. Ebell MH. Choosing between warfarin (Coumadin) and aspirin therapy for patients with atrial fibrillation. Am Fam Physician. 2005;71(12):2348-2350.

123. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med. 2003;163(13):1580-1586.

124. Bristol-Myers Squibb Company. Medication Guide: Coumadin (Warfarin Sodium) Tablets. Available at https://packageinserts.bms.com/medguide/medguide_coumadin.pdf. Last accessed October 2, 2020.

125. Verheugt FWA. Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nature Reviews Cardiology. 2010;7(3):149-154.

126. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

127. U.S. Food and Drug Administration. FDA Drug Safety Communication: Pradaxa (Dabigatran Etexilate Mesylate) Should Not Be Used in Patients with Mechanical Prosthetic Heart Valves. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-pradaxa-dabigatran-etexilate-mesylate-should-not-be-used-patients. Last accessed October 2, 2020.

128. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397-402.

129. Hills MT. FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation. Available at https://www.stopafib.org/newsitem.cfm/NEWSID/287/Pradaxa%20approved%20to%20prevent%20afib%20strokes/dabigatran%20approved%20for%20atrial%20fibrillation%20stroke%20preventio. Last accessed October 2, 2020.

130. McCarty D, Robinson A. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. Ther Adv Cardiovasc Dis. 2016;10(1):37-49.

131. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

132. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

133. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.

134. Cannom DS. Atrial fibrillation: nonpharmacologic approaches. Am J Cardiol. 2000;85(10A):25-35.

135. Agency for Healthcare Research and Quality. Radiofrequency Ablation for Atrial Fibrillation: A Guide for Adults. Available at https://www.ncbi.nlm.nih.gov/books/NBK45597. Last accessed October 2, 2020.

136. Greenberg ML. Catheter Ablation. Available at https://emedicine.medscape.com/article/1828541-overview#a01. Last accessed October 2, 2020.

137. Saremi F, Tafti M. The role of computed tomography and magnetic resonance imaging in ablation procedures for treatment of atrial fibrillation. Semin Ultrasound CT MR. 2009;30(2):125-156.

138. Stabile G, Turco P, La Rocca V, Nocerino P, Stabile E, De Simone A. Is pulmonary vein isolation necessary for curing atrial fibrillation? Circulation. 2003;108(6):657-660.

139. Centurion OA, Shimizu A. Rate control strategy elevated to primary treatment for atrial fibrillation: has the last word already been spoken? J Atr Fibrillation. 2014;7(4):1152.

140. Ernst S, Kuck KH. Current status of catheter ablation for atrial fibrillation. Herz. 2006;31(2):113-117.

141. Stuehlinger M, Hoenig S, Spuller K, et al. CoolLoop® First: a first in man study to test a novel circular cryoablation system in paroxysmal atrial fibrillation. J Atr Fibrillation. 2015;8(3):1287.

142. Kuchynka P, Podzimkova J, Masek M, et al. The role of magnetic resonance imaging and cardiac computed tomography in the assessment of left atrial anatomy, size, and function. Biomed Res Int. 2015;247865.

143. Leong DP, Dokainish H. Left atrial volume and function in patients with atrial fibrillation. Curr Opin Cardiol. 2014;29(5):437-444.

144. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management In Primary and Secondary Care. London: Royal College of Physicians; 2006.

145. Magee MJ, Herbert MA, Dewey TM, et al. Atrial fibrillation after coronary artery bypass grafting surgery: development of a predictive risk algorithm. Ann Thorac Surg. 2007;83:1707-1712.

146. El-Chami MF, Kilgo P, Thourani V, et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol. 2010;555:1370-1376.

147. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291(14):1720-1729.

148. Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure—five more years. N Engl J Med. 2004;351(23):2437-2440.

149. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013;(1):CD003611.

150. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2016;(5):CD008493.

151. Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg. 2012;147(2):181-189.

152. Zebis LR, Christensen TD, Kristiansen IS, Hjortdal VE. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery. Ann Thorac Surg. 2008;85(1):28-32.

153. Zebis LR, Christensen TD, Thomsen HF, et al. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. Ann Thorac Surg. 2007;83(4):1326-1331.

154. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edition. Chest. 2008;133(6 Suppl):546S-592S.

155. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 (2 Suppl):e531S-e575S.

156. Ellis CR. Wolff-Parkinson-White Syndrome. Available at https://emedicine.medscape.com/article/159222-overview. Last accessed October 2, 2020.

157. Bennett D. Wolff-Parkinson-White syndrome. In: Bennett's Cardiac Arrhythmias: Practical Notes on Interpretation and Treatment. 8th ed. Hoboken, NJ: Wiley-Blackwell; 2013.

158. Triedman JK. Management of asymptomatic Wolff-Parkinson-White syndrome. Heart. 2009;95:1628-1634.

Evidence-Based Practice Recommendations Citations

1. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):p1121-p1201. Available at https://journal.chestnet.org/article/S0012-3692(18)32244-X/fulltext. Last accessed October 12, 2020.

2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-e151. Available at https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665. Last accessed October 12, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.